Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05052333 · ClinicalTrials.gov registry record
Examine the Psychosocial Impacts of COVID-19 Pandemic.
A clinical trial of COVID-19 Pandemic and Psychosocial Impacts, sponsored by University of Otago.
- Completed
- Registry status
- 2,574
- Enrollment target
- 9
- Study locations
NCT05052333: Completed study of COVID-19 Pandemic and Psychosocial Impacts, sponsored by University of Otago.
NCT05052333 is a study of COVID-19 Pandemic and Psychosocial Impacts that has completed, run by University of Otago. The registered enrollment target is 2,574 participants, above the 310-participant average among 3 other COVID-19 Pandemic trials with a reported enrollment target (730% higher). The trial reports 9 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05052333, a study of COVID-19 Pandemic and Psychosocial Impacts, has completed, sponsored by University of Otago.
- COMPLETED
- Registry status
- 2,574 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is an observational study examining the psychosocial impacts of the COVID-19 pandemic in seven low-and-middle income countries (Indonesia, Iran, Iraq, Malaysia, Pakistan, Somaliland, and Turkiye). The data was obtained on standardised measures of wellbeing (WHO Well-Being Index), psychological distress (Kessler 10), post-traumatic stress (PTSD Checklist for DSM-5), post-traumatic growth (Posttraumatic Growth Inventory), and a novel pandemic-related stress (COVID Psychosocial Impacts Scale). Data was collected employing either a unilingual (in native language) or bilingual online survey (with English as a second language) from participants (N=2574) aged 18 and above using a non-probability convenient sampling. The findings enabled us to examine the psychosocial impacts of COVID-19, validate the translations of the CPIS and standardized measures; and determine the trajectory of study variables with pandemic exposure.
Primary Outcome
To explore the psychosocial impacts of the COVID-19 pandemic on self-report measures of wellbeing (WHO-5), psychological distress (K10), post-traumatic stress (PCL-5), post-traumatic growth (PTGI), and pandemic-related stress (CPIS) in seven LMICs. The data will be collected employing a unilingual (Indonesia, Somaliland, Turkey) or bilingual (Iran, Iraq, Malaysia, Pakistan) survey. With-in-subjects and between-subjects designs together with exploratory regression analyses will be employed to cha
Conditions Studied
Study Locations (9)
Other
- Universitas Ahmad Dahlan - Yogyakarta
- Universitas Gadjah Mada - Yogyakarta
- University of Social Welfare and Rehabilitation Sciences - Tehran
- Ibn Sina University of Medical and Pharmaceutical Sciences - Baghdad
- Mustansiriyah University - Baghdad
- Universiti Malaya - Kuala Lumpur
- International Islamic University - Islamabad
- Hasan Kalyoncu Üniversitesi - Gaziantep
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,574 participants |
| Start Date | 2021-12-01 |
| Est. Completion | 2023-10-31 |
What the finished NCT05052333 record still lists
NCT05052333 is an observational study that tracks outcomes without assigning an intervention. Its 2,574 participants enrollment target places it among the larger protocols in the corpus, above the 310-participant average among 3 other COVID-19 Pandemic trials with a reported enrollment target (730% higher).
The record links to 2 conditions, with COVID-19 Pandemic appearing as the primary indexed condition, and to 0 interventions.
NCT05052333 lists 9 locations in 2 states (Other, Washington).
Frequently Asked Questions
What is clinical trial NCT05052333 about?
NCT05052333 is a clinical study titled "Examine the Psychosocial Impacts of COVID-19 Pandemic.". This is an observational study examining the psychosocial impacts of the COVID-19 pandemic in seven low-and-middle income countries (Indonesia, Iran, Iraq, Malaysia, Pakistan, Somaliland, and Turkiye). The data was obtained on standardised measures of wellbeing (WHO Well-Being Index), psychological ...
What is the current status of trial NCT05052333?
This trial is currently completed. The enrollment target is 2,574 participants. The study started on 2021-12-01. Estimated completion is 2023-10-31.
What conditions does trial NCT05052333 study?
This clinical trial studies the following conditions: COVID-19 Pandemic, Psychosocial Impacts.
Who is sponsoring clinical trial NCT05052333?
This trial is sponsored by University of Otago, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05052333 being conducted?
This trial has 9 study locations across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19 Pandemic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06018285 · 2,572 participants · NA
Stepped Approach to Reducing Risk of Suicide in Primary Care
- NCT06370520 · 2,592 participants
Screening Emotions in Adolescents at the Hospital for mTBI
- NCT06033950 · 2,600 participants · Phase 3
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
- NCT06574672 · 2,600 participants · NA
Embedded Palliative Care in the MICU
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI